organization · Reporting owner
Foresite Capital Management IV, LLC
Disclosed activity across 5 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 10x Genomics, Inc.TXG · Entity 2172 | 10% owner | September 11, 2019 | September 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
10x Genomics, Inc.
Report date September 11, 2019 · Filed September 12, 2019
Jointly reported with Foresite Capital Management I, LLC, Foresite Capital Fund I, L.P., Foresite Capital Management II, LLC, Foresite Capital Fund II, L.P., Foresite Capital Fund IV, L.P., Tananbaum James B.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A-2 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2019-09-11 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Each share of Series A-2 Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series A-2 Convertible Preferred Stock. F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2019-09-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: Each share of Series B Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series B Convertible Preferred Stock. F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2019-09-11 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: Each share of Series B Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series B Convertible Preferred Stock. F5: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2019-09-11 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F4: Each share of Series C Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series C Convertible Preferred Stock. F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Series C Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2019-09-11 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F4: Each share of Series C Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series C Convertible Preferred Stock. F5: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-2 Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series A-2 Convertible Preferred Stock.
F2: The shares are owned directly by Foresite Capital Fund I, L.P. ("FCF I"). Foresite Capital Management I, LLC ("FCM I"), the general partner of FCF I, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM I, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM I and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM I and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: Each share of Series B Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series B Convertible Preferred Stock.
F4: Each share of Series C Convertible Preferred Stock is convertible, for no additional consideration, into one (1) share of Class B Common Stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the Issuer. There is no expiration date for the Series C Convertible Preferred Stock.
F5: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AERIE PHARMACEUTICALS INC
Report date February 27, 2020 · Filed March 02, 2020
Jointly reported with Foresite Capital Management II, LLC, Foresite Capital Fund II, L.P., Foresite Capital Fund III, L.P., Foresite Capital Fund IV, L.P., Foresite Capital Management III, LLC, Tananbaum James B.
Section 16 reporting ended · disclosed 2020-03-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,369,938 |
Reported balance
After 2020-02-27 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-02-27 · Sale · Disposed 302,776 · Balance 1,369,938 F1: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,925,020 |
Reported balance
After 2020-02-27 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-02-27 · Sale · Disposed 425,457 · Balance 1,925,020 F2: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,229,633 |
Reported balance
After 2020-02-27 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2020-02-27 · Sale · Disposed 271,767 · Balance 1,229,633 F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F2: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Aclaris Therapeutics, Inc.
Report date November 01, 2021 · Filed November 03, 2021
Jointly reported with Foresite Capital Management III, LLC, Foresite Capital Fund III, L.P., Foresite Capital Fund IV, L.P., Foresite Capital Management V, LLC, Foresite Capital Fund V, L.P., Tananbaum James B.
Section 16 reporting ended · disclosed 2021-11-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-11-01 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-11-01 · Other · Disposed 1,954,904 · Balance 0 F1: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F2: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 8,276 |
Reported balance
After 2021-11-01 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2021-11-01 · Other · Acquired 8,276 · Balance 8,276 F5: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended. F6: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,399,034 |
Reported balance
Holding disclosure · report date 2021-11-01 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,399,034 F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,258,243 |
Reported balance
Holding disclosure · report date 2021-11-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,258,243 F4: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 1, 2021, Foresite Capital Fund III, L.P. ("Fund III") distributed, for no consideration, 1,954,904 shares of the Issuer's Common Stock (the "Fund III Shares") to its limited partners and to Foresite Capital Management III, LLC ("FCM III"), the general partner of Fund III, representing each such partner's pro rata interest in such Fund III Shares. On the same date, FCM III distributed, for no consideration, the Fund III Shares it received in the distribution by Fund III to its members, representing each such member's pro rata interest in such Fund III Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.
F2: The shares are owned directly by Fund III. FCM III is the general partner of Fund III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum") is the sole managing member of FCM III and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM IV and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F4: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Mr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F5: Represents shares received by the James B. Tananbaum and Dana Shonfeld Tananbaum Family Trust pursuant to pro rata distributions by Fund III and FCM III, for no consideration, of shares of the Issuer's Common Stock to their respective partners or members, as applicable. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and/or 16a-9 of the Securities Exchange Act of 1934, as amended.
F6: These shares are held of record by a family trust for which Mr. Tananbaum is a trustee. Each of the Reporting Persons disclaims the existence of a "group" and, other than Mr. Tananbaum, disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that any such person is the beneficial owner of such securities, except to the extent of such person's pecuniary interest therein, if any.
Eikon Therapeutics, Inc.
Report date February 04, 2026 · Filed February 06, 2026
Jointly reported with Foresite Capital Fund IV, L.P., Foresite Capital Management V, LLC, Foresite Capital Fund V, L.P., Foresite Capital Opportunity Management V, LLC, Foresite Capital Opportunity Fund V, L.P., Foresite Capital VI-A Management, LLC, Foresite Capital VI-A, LLC
Section 16 reporting ended · disclosed 2026-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,340,878 |
Reported balance
After 2026-02-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-02-04 · Conversion · Acquired 1,340,878 · Balance 1,340,878 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,676,399 |
Reported balance
After 2026-02-04 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-02-04 · Conversion · Acquired 335,521 · Balance 1,676,399 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,714,254 |
Reported balance
After 2026-02-04 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 1,714,254 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,943,682 |
Reported balance
After 2026-02-04 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-02-04 · Conversion · Acquired 229,428 · Balance 1,943,682 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 697,885 |
Reported balance
After 2026-02-04 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2026-02-04 · Conversion · Acquired 697,885 · Balance 697,885 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 735,740 |
Reported balance
After 2026-02-04 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 735,740 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 737,366 |
Reported balance
After 2026-02-04 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2026-02-04 · Conversion · Acquired 1,626 · Balance 737,366 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 804,573 |
Reported balance
After 2026-02-04 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2026-02-04 · Conversion · Acquired 67,207 · Balance 804,573 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,263,428 |
Reported balance
After 2026-02-04 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2026-02-04 · Conversion · Acquired 458,855 · Balance 1,263,428 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 348,942 |
Reported balance
After 2026-02-04 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2026-02-04 · Conversion · Acquired 348,942 · Balance 348,942 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 386,797 |
Reported balance
After 2026-02-04 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2026-02-04 · Conversion · Acquired 37,855 · Balance 386,797 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 387,719 |
Reported balance
After 2026-02-04 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2026-02-04 · Conversion · Acquired 922 · Balance 387,719 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 425,852 |
Reported balance
After 2026-02-04 transaction · row 13
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 13 · 2026-02-04 · Conversion · Acquired 38,133 · Balance 425,852 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 408,725 |
Reported balance
After 2026-02-04 transaction · row 14
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 14 · 2026-02-04 · Conversion · Acquired 408,725 · Balance 408,725 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,318,983 |
Reported balance
After 2026-02-04 transaction · row 15
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 15 · 2026-02-04 · Purchase · Acquired 55,555 · Balance 1,318,983 F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-02-04 · Conversion · Disposed 10,000,000 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-02-04 · Conversion · Disposed 2,502,252 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-02-04 · Conversion · Disposed 5,204,684 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2026-02-04 · Conversion · Disposed 2,602,342 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2026-02-04 · Conversion · Disposed 282,317 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 23
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 23 · 2026-02-04 · Conversion · Disposed 3,048,192 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 24
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 24 · 2026-02-04 · Conversion · Disposed 12,123 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 25
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 25 · 2026-02-04 · Conversion · Disposed 6,878 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 26
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 26 · 2026-02-04 · Conversion · Disposed 501,219 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 27
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 27 · 2026-02-04 · Conversion · Disposed 284,392 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 28
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 28 · 2026-02-04 · Conversion · Disposed 1,711,025 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2026-02-04 transaction · row 29
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 29 · 2026-02-04 · Conversion · Disposed 3,422,051 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date. F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $43.59 · Expires 2030-02-14 | IndirectSee Footnote | 17,092 |
Reported balance
Holding disclosure · report date 2026-02-04 · row 30
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 30 · Balance 17,092 F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $43.59 · Expires 2030-02-14 | IndirectSee Footnote | 34,185 |
Reported balance
Holding disclosure · report date 2026-02-04 · row 31
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 31 · Balance 34,185 F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the closing of the Issuer's initial public offering of its Common Stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock, Series B-1 Preferred Stock, Series C Preferred Stock, Series C-1 Preferred Stock and Series D Preferred Stock automatically converted into approximately 0.1340878 shares of Common Stock and has no expiration date.
F2: The shares are held of record by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM IV, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund IV, disclaims beneficial ownership of the shares held by Fund IV, except to the extent of such person's pecuniary interest in such securities.
F3: The shares are held of record by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over such shares. James B. Tananbaum ("Tananbaum"), the managing member of FCM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and, other than Fund V, disclaims beneficial ownership of the shares held by Fund V, except to the extent of such person's pecuniary interest in such securities.
F4: The shares are held of record by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FCOM V, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Opportunity Fund V, disclaims beneficial ownership of the shares held by Opportunity Fund V, except to the extent of such person's pecuniary interest in such securities.
F5: The shares are held of record by Foresite Capital VI-A, LLC ("Fund VI-A"). Foresite Capital VI-A Management, LLC ("FC VI-A Management") is the general partner of Fund VI-A and may be deemed to have sole voting and dispositive power over such shares. Tananbaum, the managing member of FC VI-A Management, may be deemed to have sole voting and dispositive power over such shares. Each of the Reporting Persons disclaims the existence of a "group", as defined in Rule 13d-5 of the Exchange Act, and, other than Fund VI-A, disclaims beneficial ownership of the shares held by Fund VI-A, except to the extent of such person's pecuniary interest in such securities.
Kinnate Biopharma Inc.
Report date April 03, 2024 · Filed April 05, 2024
Jointly reported with Foresite Capital Fund IV, L.P., Foresite Capital Management V, LLC, Foresite Capital Fund V, L.P., Foresite Capital Opportunity Management V, LLC, Foresite Capital Opportunity Fund V, L.P.
Section 16 reporting ended · disclosed 2024-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-04-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-04-03 · Disposition to issuer · Disposed 9,671,643 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share. F2: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-04-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-04-03 · Disposition to issuer · Disposed 3,525,957 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share. F3: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2024-04-03 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-04-03 · Disposition to issuer · Disposed 520,711 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share. F4: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger, dated February 16, 2024, by and between the Issuer, XOMA Corporation and XRA 1 Corp. in exchange for (i) $2.5879 in cash per share, plus (ii) one non-transferable contingent value right per share.
F2: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F3: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
F4: The shares are owned directly by Foresite Capital Opportunity Fund V, L.P. ("Opportunity Fund V"). Foresite Capital Opportunity Management V, LLC ("FCOM V") is the general partner of Opportunity Fund V and may be deemed to have sole voting and dispositive power over these shares. Dr. Tananbaum is the sole managing member of FCOM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCOM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCOM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2020 Filed Dec 4, 2020 20:57 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantCommon Stock | 375,000 | $20.00 | $7,500,000.00 |
DisclosureSEC source: 0001209191-20-061877 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 375,000 F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund V, L.P. ("Fund V"). Foresite Capital Management V, LLC ("FCM V") is the general partner of Fund V and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum") is the sole managing member of FCM V and may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM V and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM V or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 20:57 UTC | Kinnate Biopharma Inc. KNTE · Entity 92187 | GrantCommon Stock | 500,000 | $20.00 | $10,000,000.00 |
DisclosureSEC source: 0001209191-20-061877 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management V, LLC · CIK 0001792206 · 10% owner Foresite Capital Fund V, L.P. · CIK 0001792204 · 10% owner Foresite Capital Opportunity Management V, LLC · CIK 0001792207 · 10% owner Foresite Capital Opportunity Fund V, L.P. · CIK 0001792205 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 500,000 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("Fund IV"). Foresite Capital Management IV, LLC ("FCM IV") is the general partner of Fund IV and may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Dr. Tananbaum"), in his capacity as the sole managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and Dr. Tananbaum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV or Dr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:01 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 271,767 | $17.07 | $4,639,062.69 |
DisclosureSEC source: 0001209191-20-014562 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,229,633 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:01 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 425,457 | $17.07 | $7,262,550.99 |
DisclosureSEC source: 0001209191-20-014562 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,925,020 F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 22:01 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | SaleCommon Stock | 302,776 | $17.07 | $5,168,386.32 |
DisclosureSEC source: 0001209191-20-014562 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,369,938 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 23:05 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherPut Option (obligation to purchase) · Derivative | 289 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001209191-19-061835 · doc4.xml · derivative · entry 4 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 28,900 shares Expires 2019-12-20 F4 · derivative.exercise_date: The option may be exercised at any time on or prior to the expiration date. F5 · balance_after: Before the reporting persons became subject to Section 16, FCF IV wrote a put option for 100,500 shares of the Issuer's common stock. The put option has now been exercised in its entirety. F6 · ownership.nature: The options are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these options. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these options. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these options except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these options for purposes of Section 16 or any other purpose. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 23:05 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherCommon Stock | 28,900 | $30.00 | $867,000.00 |
DisclosureSEC source: 0001209191-19-061835 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,501,400 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| December 03, 2019 Filed Dec 6, 2019 00:03 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherPut Option (obligation to purchase) · Derivative | 266 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059392 · doc4.xml · derivative · entry 6 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 289 Underlying: Common Stock · 26,600 shares Expires 2019-12-20 F4 · derivative.exercise_date: The option may be exercised at any time on or prior to the expiration date. F7 · balance_after: Before the reporting persons became subject to Section 16, FCF IV wrote a put option for 100,500 shares of the Issuer's common stock. The put option has now been exercised for an aggregate of 71,600 shares. A portion of the short put remains open, and therefore FCF IV may be obligated to purchase an additional 28,900 shares of the Issuer's common stock in the event the holder of the put option elects to exercise the remainder. F6 · ownership.nature: The options are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these options. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these options. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these options except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these options for purposes of Section 16 or any other purpose. Read SEC document |
| December 03, 2019 Filed Dec 6, 2019 00:03 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherCommon Stock | 26,600 | $30.00 | $798,000.00 |
DisclosureSEC source: 0001209191-19-059392 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,472,500 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| November 26, 2019 Filed Dec 6, 2019 00:03 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherPut Option (obligation to purchase) · Derivative | 44 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059392 · doc4.xml · derivative · entry 5 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 555 Underlying: Common Stock · 4,400 shares Expires 2019-12-20 F4 · derivative.exercise_date: The option may be exercised at any time on or prior to the expiration date. F5 · balance_after: Before the reporting persons became subject to Section 16, FCF IV wrote a put option for 100,500 shares of the Issuer's common stock. The put option has now been exercised for an aggregate of 45,000 shares. A portion of the short put remains open, and therefore FCF IV may be obligated to purchase an additional 55,500 shares of the Issuer's common stock in the event the holder of the put option elects to exercise the remainder. F6 · ownership.nature: The options are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these options. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these options. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these options except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these options for purposes of Section 16 or any other purpose. Read SEC document |
| November 26, 2019 Filed Dec 6, 2019 00:03 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherCommon Stock | 4,400 | $30.00 | $132,000.00 |
DisclosureSEC source: 0001209191-19-059392 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,445,900 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 23:11 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherPut Option (obligation to purchase) · Derivative | 199 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001209191-19-057029 · doc4.xml · derivative · entry 6 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 599 Underlying: Common Stock · 19,900 shares Expires 2019-12-20 F4 · derivative.exercise_date: The option may be exercised at any time on or prior to the expiration date. F7 · balance_after: Before the reporting persons became subject to Section 16, FCF IV wrote a put option for 100,500 shares of the Issuer's common stock. The put option has now been exercised for an aggregate of 40,600 shares. A portion of the short put remains open, and therefore FCF IV may be obligated to purchase an additional 59,900 shares of the Issuer's common stock in the event the holder of the put option elects to exercise the remainder. F6 · ownership.nature: The options are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these options. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these options. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these options except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these options for purposes of Section 16 or any other purpose. Read SEC document |
| November 15, 2019 Filed Nov 18, 2019 23:11 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherCommon Stock | 19,900 | $30.00 | $597,000.00 |
DisclosureSEC source: 0001209191-19-057029 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,441,500 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 23:11 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherPut Option (obligation to purchase) · Derivative | 57 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001209191-19-057029 · doc4.xml · derivative · entry 5 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 798 Underlying: Common Stock · 5,700 shares Expires 2019-12-20 F4 · derivative.exercise_date: The option may be exercised at any time on or prior to the expiration date. F5 · balance_after: Before the reporting persons became subject to Section 16, FCF IV wrote a put option for 100,500 shares of the Issuer's common stock. The put option has now been exercised for an aggregate of 20,700 shares. A portion of the short put remains open, and therefore FCF IV may be obligated to purchase an additional 79,800 shares of the Issuer's common stock in the event the holder of the put option elects to exercise the remainder. F6 · ownership.nature: The options are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these options. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these options. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these options except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these options for purposes of Section 16 or any other purpose. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 23:11 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherCommon Stock | 5,700 | $30.00 | $171,000.00 |
DisclosureSEC source: 0001209191-19-057029 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,421,600 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 19:52 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherPut Option (obligation to purchase) · Derivative | 150 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055965 · doc4.xml · derivative · entry 4 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 855 Underlying: Common Stock · 15,000 shares Expires 2019-12-20 F4 · derivative.exercise_date: The option may be exercised at any time on or prior to the expiration date. F5 · balance_after: Before the reporting persons became subject to Section 16, FCF IV wrote a put option for 100,500 shares of the Issuer's common stock. The put option was partially exercised by its holder for 15,000 shares. A portion of the short put remains open, and therefore FCF IV may be obligated to purchase an additional 85,500 shares of the Issuer's common stock in the event the holder of the put option elects to exercise the remainder. F6 · ownership.nature: The options are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these options. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these options. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these options except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these options for purposes of Section 16 or any other purpose. Read SEC document |
| November 07, 2019 Filed Nov 12, 2019 19:52 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | OtherCommon Stock | 15,000 | $30.00 | $450,000.00 |
DisclosureSEC source: 0001209191-19-055965 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,415,900 F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 05, 2019 Filed Sep 7, 2019 00:28 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 15,700 | $18.42 | $289,194.00 |
DisclosureSEC source: 0001209191-19-048830 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,350,477 F4 · price: This transaction was executed in multiple trades at prices ranging from $18.25 to $18.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 04, 2019 Filed Sep 7, 2019 00:28 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 90,900 | $18.48 | $1,679,832.00 |
DisclosureSEC source: 0001209191-19-048830 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,400,900 F1 · price: This transaction was executed in multiple trades at prices ranging from $18.12 to $18.75. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 04, 2019 Filed Sep 7, 2019 00:28 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 9,300 | $18.48 | $171,864.00 |
DisclosureSEC source: 0001209191-19-048830 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,334,777 F1 · price: This transaction was executed in multiple trades at prices ranging from $18.12 to $18.75. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 00:38 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 15,100 | $21.45 | $323,895.00 |
DisclosureSEC source: 0001209191-19-048394 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,325,477 F4 · price: This transaction was executed in multiple trades at prices ranging from $21.23 to $21.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| September 03, 2019 Filed Sep 5, 2019 00:38 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 34,900 | $20.54 | $716,846.00 |
DisclosureSEC source: 0001209191-19-048394 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,310,377 F3 · price: This transaction was executed in multiple trades at prices ranging from $20.23 to $21.20. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 30, 2019 Filed Sep 5, 2019 00:38 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 25,000 | $21.36 | $534,000.00 |
DisclosureSEC source: 0001209191-19-048394 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,275,477 F1 · price: This transaction was executed in multiple trades at prices ranging from $21.00 to $21.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 23, 2019 Filed Aug 24, 2019 00:52 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 38,300 | $23.42 | $896,986.00 |
DisclosureSEC source: 0001209191-19-047387 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,250,477 F3 · price: This transaction was executed in multiple trades at prices ranging from $23.295 to $23.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 22, 2019 Filed Aug 24, 2019 00:52 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 6,700 | $23.68 | $158,656.00 |
DisclosureSEC source: 0001209191-19-047387 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,212,177 F2 · price: This transaction was executed in multiple trades at prices ranging from $23.48 to $23.75. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 21, 2019 Filed Aug 24, 2019 00:52 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 1,153 | $23.25 | $26,807.25 |
DisclosureSEC source: 0001209191-19-047387 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,205,477 F1 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 20, 2019 Filed Aug 21, 2019 00:27 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 50,000 | $23.21 | $1,160,500.00 |
DisclosureSEC source: 0001209191-19-046913 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,204,324 F4 · price: This transaction was executed in multiple trades at prices ranging from $22.82 to $23.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 00:27 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 3,847 | $23.34 | $89,788.98 |
DisclosureSEC source: 0001209191-19-046913 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,154,324 F3 · price: This transaction was executed in multiple trades at prices ranging from $23.22 to $23.42. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 16, 2019 Filed Aug 21, 2019 00:27 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 100,000 | $24.23 | $2,423,000.00 |
DisclosureSEC source: 0001209191-19-046913 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,150,477 F1 · price: This transaction was executed in multiple trades at prices ranging from $23.73 to $24.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 14, 2019 Filed Aug 15, 2019 00:15 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 100,000 | $23.73 | $2,373,000.00 |
DisclosureSEC source: 0001209191-19-046012 · doc4.xml · nonDerivative · entry 4 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,050,477 F5 · price: This transaction was executed in multiple trades at prices ranging from $23.50 to $24.05. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · ownership.nature: The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 00:15 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 178,903 | $25.52 | $4,565,604.56 |
DisclosureSEC source: 0001209191-19-046012 · doc4.xml · nonDerivative · entry 3 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,310,000 F4 · price: This transaction was executed in multiple trades at prices ranging from $25.16 to $25.70. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 13, 2019 Filed Aug 15, 2019 00:15 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 71,097 | $24.92 | $1,771,737.24 |
DisclosureSEC source: 0001209191-19-046012 · doc4.xml · nonDerivative · entry 2 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,131,097 F3 · price: This transaction was executed in multiple trades at prices ranging from $24.15 to $25.15. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
| August 12, 2019 Filed Aug 15, 2019 00:15 UTC | AERIE PHARMACEUTICALS INC AERI · Entity 122210 | PurchaseCommon Stock | 189,555 | $24.43 | $4,630,828.65 |
DisclosureSEC source: 0001209191-19-046012 · doc4.xml · nonDerivative · entry 1 Foresite Capital Management II, LLC · CIK 0001594912 · 10% owner Foresite Capital Fund II, L.P. · CIK 0001594914 · 10% owner Foresite Capital Management III, LLC · CIK 0001645157 · 10% owner Foresite Capital Fund III, L.P. · CIK 0001645158 · 10% owner Foresite Capital Management IV, LLC · CIK 0001704132 · 10% owner Foresite Capital Fund IV, L.P. · CIK 0001704131 · 10% owner Tananbaum James B. · CIK 0001581754 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,060,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $23.99 to $24.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · ownership.nature: The shares are owned directly by Foresite Capital Fund IV, L.P. ("FCF IV"). Foresite Capital Management IV, LLC ("FCM IV"), the general partner of FCF IV, may be deemed to have sole voting and dispositive power over these shares. Mr. Tananbaum, in his capacity as managing member of FCM IV, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM IV and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM IV and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.